Supernus Pharmaceuticals has been granted a patent for methods of making derivatives and prodrugs of substituted morpholines or their salts. The patent covers the manufacturing process for morpholine derivatives with specific chemical structures. GlobalData’s report on Supernus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Supernus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Supernus Pharmaceuticals's grant share as of May 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Method of making morpholine derivatives for pharmaceutical use
A recently granted patent (Publication Number: US11964951B2) discloses a method for manufacturing a morpholine derivative of formula Ilf or a pharmaceutically acceptable salt thereof. The method involves several steps, including reacting a compound of a specific formula, utilizing a phase transfer catalyst such as tetrabutylammonium hydrogen sulfate, and employing a sulfonyl halide compound like p-toluenesulfonyl chloride. The process also includes cyclization using NaOH, washing the crude product chlorocarbamate compound with an alkane solvent, and utilizing a metal salt or compound like cesium salt or cesium carbonate in certain steps.
Furthermore, the method described in the patent involves specific conditions and parameters for each step, such as heating to a minimum temperature of 30°C in step (a), performing step (b) at room temperature, and utilizing particular substituents for R1, R2, R3, R4, and R5 in the formula. The patent also mentions the enantiomeric purity of the final product, with the possibility of obtaining the (S)—HCl salt with greater than 90% of one enantiomer. Overall, the method outlined in the patent provides a detailed and systematic approach to synthesizing the morpholine derivative, offering potential applications in the pharmaceutical industry.
To know more about GlobalData’s detailed insights on Supernus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
